Submitted by web@researchtop... on Fri, 05/25/2012 - 16:29
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:27
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:26
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:25
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:22
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:21
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:20
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:19
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:18
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:15
Submitted by web@researchtop... on Fri, 05/25/2012 - 16:14
Submitted by web@researchtop... on Fri, 05/25/2012 - 15:37
Submitted by mphilemon@resea... on Fri, 05/25/2012 - 15:18
Select Publications
Bachelot T et al. TAMRAD: A GINECO randomized Phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). San Antonio Breast Cancer Symposium 2010;Abstract S1-6.
Submitted by mphilemon@resea... on Fri, 05/25/2012 - 15:06
TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.
OVERVIEW OF ACTIVITY
Submitted by web@researchtop... on Thu, 05/24/2012 - 13:42